does tirzepatide cause hormonal changes Spotting? Side Effects Explained Tirzepatide and Menstrual Cycle: Effects
Description
Why Patients in Missouri and Illinois Choose Ozempic from DermaSpecialty
Non-GLP-1 obesity drugs are emerging, with this landscape expected to surge 50-fold over the next five years, generating $15.5bn in 2031.
Semaglutide has shown promise in reducing liver fat accumulation while supporting weight loss
Phase 3 Results (REIMAGINE-2, Feb 2026): HbA1c reduction of up to 1.91 points, outperforming semaglutide alone Weight loss of up to 14.2% at 68 weeks in adults with type 2 diabetes and obesity In weight-management evaluation, diabetics achieved ~15.7% weight loss vs 3.1% with placebo Regulatory update: Novo Nordisk filed for FDA approval (Dec 2025) for weight management, supported by the REDEFINE clinical program
These findings highlight the potential of GLP-1RAs for retinal neuroprotection, but further studies are needed to elucidate their applicability in glaucoma.
Despite their therapeutic potential, concerns regarding tolerability, adverse reactions, and high costs may impact patient compliance
